Tokyo, Japan – NEC Corporation and Biomy, Inc. have now signed a Memorandum of Understanding to develop and extend artificial intelligence and deep learning-based analytical platforms for digital pathology. This strategic collaboration aims to enhance precision medicine and cancer care by using high-end AI technologies for pathology diagnostics.
Precision medicine usually means that treatments are matched with the profile of the patient reducing side effects and enhancing outcomes. The cooperation between NEC and Biomy takes biomedical mining to AI/DL algorithms that would work on digital pathology images where the biomarkers identified would guide personalized patient treatment decisions. DeepPathFinder™, Biomy’s proprietary platform, uses AI to automatically classify cells and tissues in pathology and identifies and detects immune cells such as lymphocytes and plasma cells from H&E stained images. It also generates quantitative measures important for understanding drug efficacy and prognosis.
NEC brings decades of experience in AI and image analysis to this partnership, including expertise in regulatory approval for medical devices. As a leader in healthcare technology, NEC has supplied critical health systems such as electronic medical records to healthcare institutions across the globe. The company’s healthcare and life sciences goals dovetail with its mission to take on societal issues through the use of advanced technologies.
The partnership between NEC and Biomy has focused on three principal objectives: enhancing the DeepPathFinder™ platform to identify future pathological biomarkers using AI and deep learning (DL) technologies; automating tools and services available for marker discovery to pharmaceutical companies and academics; and finally, supporting regulatory approval processes for any medical devices utilizing AI/DL-based digitized pathology systems.
Combining their skill sets, the two advanced companies have designed tools for integration into clinical applications by biotech and pharmaceutical firms. These tools will boost the efficiency of novel biomarker discovery processes and enhance planning and outcomes in cancer treatment.
This will be followed by the introduction of these new biomarkers into clinical practice, fulfilling their precision medicine promise and changing the way cancer is diagnosed and treated with AI-powered digital pathology solutions.
Source: https://www.nec.com/en/press/202501/global_20250110_01.html
Latest Stories:
India Leads Global AI Education, Finds Bosch Tech Compass 2025
NVIDIA Revolutionizes PCs with RTX AI Garage & GeForce RTX 50 Series
NTT DATA Earns ISG Leadership Title in Generative AI Services 2024
What is your reaction?
